HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma

Jinxia Peng,1,* Ju Zhao,2,* Yumei Zhao,2 Peng Wu,2 Lantu Gou,3 Shaozhi Fu,2 Ping Chen,2 Yun Lu,2 Linglin Yang2 1Department of Oncology, People’s Hospital of Xindu District, Chengdu, Sichuan 610500, People’s Republic of China; 2Department of Oncology, The Affiliated Hospital of So...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peng J, Zhao J, Zhao Y, Wu P, Gou L, Fu S, Chen P, Lu Y, Yang L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	cervical carcinoma hela cells microparticles paclitaxel vector Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/aff2204714134de587c56768e5232913
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aff2204714134de587c56768e5232913
record_format	dspace
spelling	oai:doaj.org-article:aff2204714134de587c56768e52329132021-12-02T11:20:29ZHeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma1178-2013https://doaj.org/article/aff2204714134de587c56768e52329132020-08-01T00:00:00Zhttps://www.dovepress.com/hela-cell-derived-paclitaxel-loaded-microparticles-efficiently-inhibit-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Jinxia Peng,1,* Ju Zhao,2,* Yumei Zhao,2 Peng Wu,2 Lantu Gou,3 Shaozhi Fu,2 Ping Chen,2 Yun Lu,2 Linglin Yang2 1Department of Oncology, People’s Hospital of Xindu District, Chengdu, Sichuan 610500, People’s Republic of China; 2Department of Oncology, The Affiliated Hospital of Southwest Medical University Luzhou, Sichuan 646000, People’s Republic of China; 3West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linglin Yang Email yanglinglin2003@qq.comAim: Tumor cell-derived microparticles (MP) can function as a targeted delivery carrier for anti-tumor drugs. Here, we aimed to generate paclitaxel-loaded microparticles (MP-PTX) from HeLa cells and examined its therapeutic potential on human cervical carcinoma.Methods: MP-PTX was generated from HeLa cells by ultraviolet radiation and subsequent centrifugation. The particle size, drug loading rate, and stability of MP-PTX were examined in vitro. Flow cytometry and the MTT assay were performed to test the inhibitory effect of MP-PTX using different cell lines. Immunodeficient mice bearing HeLa cervical carcinoma were treated with 0.9% normal saline, MP, paclitaxel (PTX) (2.5 mg/kg), or MP-PTX (PTX content identical to PTX group) every day for 6 consecutive days. Tumor volume and animal survival were observed. Micro 18F-FDG PET/CT was performed to monitor the therapeutic efficacy. The proliferation activity of cells and microvessel density in tumor tissues were determined by immunohistochemical staining using Ki-67 and CD31, respectively.Results: Dynamic laser scattering measurements showed that the particle size of MP-PTX was 285.58 ± 2.95 nm and the polydispersity index was 0.104 ± 0.106. And the particle size of MP-PTX was not change at 4°C for at least one week. More than 1% of PTX in the medium could be successfully encapsulated into HeLa cell-derived MP. When compared with PTX, MP-PTX treatment significantly increased apoptosis of tumor cells and reduced their proliferation. In addition, MP-PTX showed lower toxicity to normal human umbilical vein endothelial cells (HUVEC) than PTX. In vivo studies further demonstrated that MP-PTX treatment significantly inhibited the growth of cervical carcinoma, prolonged the survival of tumor-bearing mice, and reduced the toxicity of PTX. Immunohistochemical staining revealed that MP-PTX treatment led to decreased Ki-67 positive tumor cells and decreased microvessel density in tumor tissues.Conclusion: Our results demonstrated that HeLa-derived MP-PTX significantly enhanced the anti-cancer effects of PTX with reduced toxicity, which may provide a novel strategy for the treatment of cervical carcinoma.Keywords: cervical carcinoma, HeLa cells, microparticles, paclitaxel, vectorPeng JZhao JZhao YWu PGou LFu SChen PLu YYang LDove Medical Pressarticlecervical carcinomahela cellsmicroparticlespaclitaxelvectorMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 6409-6420 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	cervical carcinoma hela cells microparticles paclitaxel vector Medicine (General) R5-920
spellingShingle	cervical carcinoma hela cells microparticles paclitaxel vector Medicine (General) R5-920 Peng J Zhao J Zhao Y Wu P Gou L Fu S Chen P Lu Y Yang L HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma
description	Jinxia Peng,1,* Ju Zhao,2,* Yumei Zhao,2 Peng Wu,2 Lantu Gou,3 Shaozhi Fu,2 Ping Chen,2 Yun Lu,2 Linglin Yang2 1Department of Oncology, People’s Hospital of Xindu District, Chengdu, Sichuan 610500, People’s Republic of China; 2Department of Oncology, The Affiliated Hospital of Southwest Medical University Luzhou, Sichuan 646000, People’s Republic of China; 3West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linglin Yang Email yanglinglin2003@qq.comAim: Tumor cell-derived microparticles (MP) can function as a targeted delivery carrier for anti-tumor drugs. Here, we aimed to generate paclitaxel-loaded microparticles (MP-PTX) from HeLa cells and examined its therapeutic potential on human cervical carcinoma.Methods: MP-PTX was generated from HeLa cells by ultraviolet radiation and subsequent centrifugation. The particle size, drug loading rate, and stability of MP-PTX were examined in vitro. Flow cytometry and the MTT assay were performed to test the inhibitory effect of MP-PTX using different cell lines. Immunodeficient mice bearing HeLa cervical carcinoma were treated with 0.9% normal saline, MP, paclitaxel (PTX) (2.5 mg/kg), or MP-PTX (PTX content identical to PTX group) every day for 6 consecutive days. Tumor volume and animal survival were observed. Micro 18F-FDG PET/CT was performed to monitor the therapeutic efficacy. The proliferation activity of cells and microvessel density in tumor tissues were determined by immunohistochemical staining using Ki-67 and CD31, respectively.Results: Dynamic laser scattering measurements showed that the particle size of MP-PTX was 285.58 ± 2.95 nm and the polydispersity index was 0.104 ± 0.106. And the particle size of MP-PTX was not change at 4°C for at least one week. More than 1% of PTX in the medium could be successfully encapsulated into HeLa cell-derived MP. When compared with PTX, MP-PTX treatment significantly increased apoptosis of tumor cells and reduced their proliferation. In addition, MP-PTX showed lower toxicity to normal human umbilical vein endothelial cells (HUVEC) than PTX. In vivo studies further demonstrated that MP-PTX treatment significantly inhibited the growth of cervical carcinoma, prolonged the survival of tumor-bearing mice, and reduced the toxicity of PTX. Immunohistochemical staining revealed that MP-PTX treatment led to decreased Ki-67 positive tumor cells and decreased microvessel density in tumor tissues.Conclusion: Our results demonstrated that HeLa-derived MP-PTX significantly enhanced the anti-cancer effects of PTX with reduced toxicity, which may provide a novel strategy for the treatment of cervical carcinoma.Keywords: cervical carcinoma, HeLa cells, microparticles, paclitaxel, vector
format	article
author	Peng J Zhao J Zhao Y Wu P Gou L Fu S Chen P Lu Y Yang L
author_facet	Peng J Zhao J Zhao Y Wu P Gou L Fu S Chen P Lu Y Yang L
author_sort	Peng J
title	HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma
title_short	HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma
title_full	HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma
title_fullStr	HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma
title_full_unstemmed	HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma
title_sort	hela cell-derived paclitaxel-loaded microparticles efficiently inhibit the growth of cervical carcinoma
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/aff2204714134de587c56768e5232913
work_keys_str_mv	AT pengj helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma AT zhaoj helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma AT zhaoy helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma AT wup helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma AT goul helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma AT fus helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma AT chenp helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma AT luy helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma AT yangl helacellderivedpaclitaxelloadedmicroparticlesefficientlyinhibitthegrowthofcervicalcarcinoma
_version_	1718396007417380864

HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma

Ejemplares similares